⚠️ Research Notice: This information is for educational and laboratory research purposes only. Not for human consumption.
GLP-1 Family
medium Confidence
Tirzepatide
Last Updated: January 2025
Key Takeaways: Tirzepatide
Tirzepatide is a GLP-1 peptide primarily researched for:
- Dual agonist (GLP-1 & GIP)
- Superior weight loss efficacy
- Improved insulin sensitivity
Research Profile
Stability Class Standard
Confidence medium
Freezable? ❌ No (Fragile)
Tirzepatide is a novel “twincretin” peptide that acts on both the GIP and GLP-1 receptors. This dual mechanism appears to offer synergistic effects on weight loss and metabolic health.
Clinical Data
Studies have shown weight reduction of up to 20% or more in non-diabetic obese adults, surpassing Semaglutide in head-to-head trials (SURMOUNT-1).
Dosage and Administration
Typically administered once weekly via subcutaneous injection.
Clinical Data & Studies
Key Benefits
- Dual agonist (GLP-1 & GIP)
- Superior weight loss efficacy
- Improved insulin sensitivity
Potential Side Effects
- Nausea
- Diarrhea
- Decreased appetite
- Indigestion
Stability Profile
Fridge (2-8°C)
Stable (~30 days)
Room Temp
Degrades moderately at room temp